Cargando…
Efficacy and safety of 400 mg efavirenz versus standard 600 mg dose when taken with tenofovir and lamivudine combination in Indian adult patients with HIV-1 infection: An open-label, interventional, randomized, non-inferiority trial
To evaluate the non-inferiority of low dose efavirenz (400 mg) to standard dose efavirenz (600 mg), when taken in combination with tenofovir and lamivudine in Indian patients with HIV-1 infection. METHODS: An open-label, interventional phase IV study with blinded assessment was conducted across 17 s...
Autores principales: | Dravid, Ameet, Pilawan, Anant S., S., Anuradha, Morkar, Dnyanesh N., Ramapuram, John T, Madhukarrao, Kulkarni Milind, Naik, K. Sunil, Bhrusundi, Milind, K. R, Raveendra, Nageswaramma, Siddabathuni, Kulkarni, Vinay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726289/ https://www.ncbi.nlm.nih.gov/pubmed/36482530 http://dx.doi.org/10.1097/MD.0000000000031982 |
Ejemplares similares
-
Safety of low dose efavirenz regimen in Indian adults with HIV-1 infection: Insights from a phase 4 interventional randomised trial
por: Dravid, Ameet N., et al.
Publicado: (2023) -
A Phase IV Study on Safety, Tolerability and Efficacy of Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate in Treatment Naïve Adult Indian Patients Living with HIV-1
por: Dravid, Ameet, et al.
Publicado: (2022) -
Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults
por: Li, Jin, et al.
Publicado: (2022) -
Efficacy and safety of a single‐tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV‐1‐infected subjects on nonnucleoside reverse transcriptase inhibitor‐containing first‐line antiretroviral therapy in Pune, India
por: Dravid, A, et al.
Publicado: (2020) -
Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India
por: Dravid, Ameet N., et al.
Publicado: (2018)